In this work, cord blood cells from 30 healthy term newborns were analyzed for complete blood counts with an automated cytometer and, in part of the sample, for surface molecules in cord blood monocytes, lymphocytes and CD34+ cells by two-color flow cytometry. Hematological parameters were as follows: WBC = 12.85 (5.24–15.10) ×109/l; platelets = 304.33 (156.00–469.00) × 109/l; Hb = 14.45 (11.90–17.82) g/dl; RBC = 3.99 (3.14–5.12) × 1012/l; MCV 107.25 (99.60–115.00) fl; reticulocytes = 157.80 (101.00–124.00) × 109/l or 3.99 (2.45–6.01)%; erythroblasts = 0.88 (0.15–2.58) per 100 WBC or 6.63 (2.86–16.80) × 109/l. The mononuclear population, as evaluated by flow cytometry, was composed of 22.9 ± 7.2% monocytes and 77.05 ± 7.24% lymphocytes, among which 46.59 ± 15.62% were T lymphocytes (43.94 ± 16.94% CD3+/CD4+ and 13.45 ± 7.46% CD3+/CD8+). CD34+ cells were on average 0.54 ± 0.24% of the mononuclear fraction. CD11c, CD49e and HLA-DR were found mainly on monocytes, and CD31 and CD62L occurred in similar levels on monocytes and lymphocytes. CD117+ cells were less than 5% of these populations. Among CD34+ cells, CD31 and HLA-DR were the molecules with higher frequencies (79.7 ± 19.9 and 65.7 ± 23.0%, respectively), followed by CD62L (41.8 ± 31.9%) and CD117 (20.1 ± 15.8%). The presence of CD11c and CD49e on CD34+ cells was low (below 10%). The results stress the phenotypic heterogeneity of cord blood CD34+ cells, and the different behavior of the cells when manipulated in vitro in different degrees of isolation.

Keywords:
Stem cells, Immunophenotyping, Adhesion molecules, Cord blood
1.
Gluckman E, Rocha V, Chastang C: Cord blood stem cell. Baillières Best Pract Res Clin Haematol 1999;12:279–292.
2.
Roy V, Verfaillie C: Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: Implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Exp Hematol 1999;27:302–312.
3.
Paloczi K: Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells. Leukemia 1999;13(suppl 1):S87–89.
4.
Nardi NB, Costa ZZA: The hematopoietic stroma. Braz J Med Biol Res 1999;32:601–609.
5.
Timeus F, Crescenzio N, Basso G, Ramenghi U, Saracco P, Gabutti V: Cell adhesion molecule expression in cord blood CD34+ cells. Stem Cells 1998;16:120–126.
6.
Saeland S, Duvert V, Caux C, Pandrau D, Favre C, Valle A, Durand I, Charbord P, de Vries J, Banchereau J: Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells. Exp Hematol 1992;20:24–33.
7.
Walka MM, Sonntag J, Kage A, Dudenhausen JW, Obladen M: Complete blood counts from umbilical cords of healthy term newborns by two automated cytometers. Acta Haematol 1998;100:167–173.
8.
Cabanas C, Sanchez-Madrid F, Acevedo A, Bellon T, Fernandez JM, Larraga V, Bernabeu C: Characterization of a CD11c-reactive monoclonal antibody (HC1/1) obtained by immunizing with phorbol ester differentiated U937 cells. Hybridoma 1988;7:167–176.
9.
Ashman LK, Aylett GW, Cambareri AC, Cole SR: Different epitopes of the CD31 antigen identified by monoclonal antibodies: Cell type-specific patterns of expression. Tissue Antigens 1991;38:199–207.
10.
Kurosawa K, Miyazawa K, Gotoh A, Katagiri T, Nishimaki J, Ashman LK, Toyama K: Immobilized anti-KIT monoclonal antibody induces ligand-independent dimerization and activation of Steel factor receptor: Biologic similarity with membrane-bound form of Steel factor rather than its soluble form. Blood 1996;87:2235–2243.
11.
Vyth-Dreese FA, Van Kooyk Y, Dellemijn TA, Melief CJ, Figdor CG: Regulatory effect of interleukin-4 (IL-4) on the expression and function of lymphocyte adhesion receptors involved in IL-2-induced cell aggregation. Immunology 1993;78:244–251.
12.
Kansas GS, Spertinin O, Stoolman LM, Tedder TF: Molecular mapping of functional domains of the leukocyte receptor for endothelium, LAM-1. J Cell Biol 1991;114:351–358.
13.
Bain BJ: Blood Cells: A Practical Guide, ed 2. London, Blackwell Science, 1996.
14.
D’Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, Carotenuto M: Flow cytometric characterization of human umbilical cord blood lymphocytes: Immunophenotypic features. Haematologica 1998;83:197–203.
15.
Keller JR, Ortiz M, Ruscetti FW: Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division. Blood 1995;86:1757–1764.
16.
Teyssier-Le Discorde M, Prost S, Nandrot E, Kirszenbaum M: Spatial and temporal mapping of c-kit and its ligand, stem cell factor expression during human embryonic haemopoiesis. Br J Haematol 1999;107:247–253.
17.
Sakabe H, Yahata N, Kimura T, Zeng ZZ, Minamiguchi H, Kaneko H, Mori KJ, Ohyashiki K, Ohyashiki JH, Toyama K, Abe T, Sonoda Y: Human cord blood-derived primitive progenitors are enriched in CD34+c-kit-cells: Correlation between long-term culture-initiating cells and telomerase expression. Leukemia 1998;12:728–734.
18.
D’Arena G, Musto P, Cascavilla N, Di Giorgio G, Zendoli F, Carotenuto M: Human umbilical cord blood: Immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells. Haematologica 1996;81:404–409.
19.
Traycoff CM, Abboud MR, Laver J, Brandt JE, Hoffman R, Law P, Ishizawa L, Srour EF: Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. Exp Hematol 1994;22:215–222.
20.
PROW, Protein Reviews On the Web: http://www.ncbi.nlm.nih.gov/prow/cd/index_molecule.htm
21.
Asosingh K, Renmans W, Van der Gucht K, Foulon W, Schors R, Van Riet I, De Waele M: Circulating CD34+ cells in cord blood and mobilized blood have a different profile of adhesion molecules than bone marrow CD34+ cells. Eur J Haematol 1998;60:153–160.
22.
Coulombel L, Auffray I, Gaugler MH, Rosenblatt M: Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol 1997;97:13–21.
23.
Watt SM, Williamson J, Genevier H, Fawcett J, Simmons DL, Hatzfeld A, Nesbitt SA, Coombe DR: The heparin binding PECAM-1 adhesion molecule is expressed by CD34+ hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes. Blood 1993;82:2649–2663.
24.
Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-Cortenbach IC, Schaasberg WP, Pinedo HM, von dem Borne AE, van der Schoot CE: Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995;85:3313–3319.
25.
Reems JA, Mielcarek M, Torok-Storb B: Differential modulation of adhesion markers with ex vivo expansion of human umbilical CD34+ progenitor cells. Biol Blood Marrow Transplant 1997;3:133–141.
26.
Mohle R, Murea S, Kirsch M, Haas R: Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol 1995;23:1535–1542.
27.
Koenig JM, Baron S, Luo D, Benson NA, Deisseroth AB: L-selectin expression enhances clonogenesis of CD34+ cord blood progenitors. Pediatr Res 1999;45:867–870.
28.
Kimura A, Kawaishi K, Sasaki A, Hyodo H, Oguma N: L-selectin expression in CD34 positive cells in chronic myeloid leukemia. Leuk Lymphoma 1998;28:399–404.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.